Moderna and Merck report Phase 3 melanoma vaccine cuts recurrence risk by 42%

Moderna and Merck announced positive Phase 3 INTerpath‑001 results for their personalized mRNA cancer vaccine, intismeran, combined with Keytruda in resected stage IIB‑IV melanoma. The trial showed a 42% reduction in recurrence or death (HR = 0.58) and a 38% reduction in distant metastasis or death (HR = 0.62) versus Keytruda alone. Results will be presented at the ESMO 2026 Presidential Symposium and the companies will engage regulators.

The companies say the data support regulatory discussions and could expand the market for the vaccine (the companies plan regulatory discussions,). Despite the positive efficacy, both stocks fell sharply on the news, reflecting investor concern over valuation and market expectations (stock declines reported in multiple sources, e.g.,).

  • 1The primary analysis showed a 42% reduction in recurrence or death (HR = 0.58, 95% CI 0.45–0.75, p < 0.001).
  • 2The same analysis showed a 38% reduction in distant metastasis or death (HR = 0.62, 95% CI 0.45–0.85, p = 0.002).
  • 3Median follow‑up was 24.6 months.
  • 4The trial enrolled 1,137 patients, randomized 2:1 to intismeran + Keytruda versus Keytruda alone.
  • 5Results will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 Presidential Symposium.

Sources